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Abstract:  The  particle  sizes  of  pharmaceutical  substances  are  important  for  their 
bioavailability. Bioavailability can be improved by reducing the particle size of the drug.  
In this study, artemisinin was micronized by the rapid expansion of supercritical solutions 
(RESS). The particle size of the unprocessed white needle-like artemisinin particles was 30 
to 1200 µm. The optimum micronization conditions are determined as follows: extraction 
temperature of 62 ° C, extraction pressure of 25 MPa, precipitation temperature 45 ° C and 
nozzle diameter of 1000 μm. Under the optimum conditions, micronized artemisinin with a 
(mean  particle  size)  MPS  of  550  nm  is  obtained.  By  analysis  of  variance  (ANOVA), 
extraction temperature and pressure have significant effects on the MPS of the micronized 
artemisinin.  The  particle  size  of  micronized  artemisinin  decreased  with  increasing 
extraction temperature and pressure. Moreover, the SEM, LC-MS, FTIR, DSC and XRD 
allowed the comparison between the crystalline initial state and the micronization particles 
obtained after the RESS process. The results showed that RESS process has not induced 
degradation of artemisinin and that processed artemisinin particles have lower crystallinity 
and melting point. The bulk density of artemisinin was determined before and after RESS 
process and the obtained results showed that it passes from an initial density of 0.554 to 
0.128 g· cm
−3 after the processing. The decrease in bulk density of the micronized powder 
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can  increase  the  liquidity  of  drug  particles  when  they  are  applied  for  medicinal 
preparations.  These  results  suggest  micronized  powder  of  artemisinin  can  be  of  great 
potential in drug delivery systems. 
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1. Introduction 
Artemisinin (chemical structure: Figure 1) is a sesquiterpene lactone with an endoperoxide function. 
It was first isolated from the Chinese traditional herb—Artemisia annua L. and its structure was first 
confirmed by Chinese scientists in the 1970s [1]. Artemisinin and its derivatives or analogues are 
currently regarded as the most promising weapons against multidrug-resistant malaria [2]. Its unique  
1,2,4-trioxane  structure  is  entirely  incompatible  with  the  traditional  antimalarial  structure-activity 
theory, which attracted the interest of many researchers [3,4]. However, artemisinin cannot be made 
into an injection due to its poor water solubility [5] and its very low oral bioavailability. Therefore, 
scientists remodel the molecular structure of artemisinin, to synthesize a series of derivatives, such as 
dihydroartemisinin, artemethe, arteether and artesunat and so on [6–8]. Although these derivatives can 
improve the solubility to a certain point, preparation techniques are difficult and costly. All of these 
limited the clinical application of artemisinin [9,10]. 
Figure 1. The chemical structure of artemisinin (the molecular weight is 282.34). 
 
The bioavailability of pharmaceuticals presented in a solid formulation strongly depends on the size, 
particle size distribution and morphology of the particles [11]. Due to  this, there is an increasing 
interest in the development of efficient micronization technologies. Different techniques have been 
applied for this purpose, including spray-drying, freeze-drying, liquid antisolvent crystallization or 
milling processes [12,13]. These technologies present several disadvantages, such as the production of 
coarse particles with broad particle size distribution, the degradation of the product due to mechanical 
or  thermal  stresses,  or  the  contamination  of  the  particles  with  organic  solvents  or  other  toxic 
substances. For this reason, different alternative precipitation methods are being investigated. Int. J. Mol. Sci. 2012, 13  5062 
 
 
Rapid expansion of supercritical solutions (RESS) is a new technology that has developed in recent 
years [14–22]. In the RESS technique, the solute is first solubilized in a supercritical fluid and the 
supercritical  solution  is  expanded  through  a  fine-diameter  nozzle.  When  a  supercritical  solution 
containing a dissolved solute is rapidly expanded across a micro-orifice, the solvent density dramatically 
decreases, leading to precipitation of the solute form the solvent [23,24]. The high supersaturation 
ratios and the homogeneous conditions attained due to the rapid expansion of a highly compressible 
supercritical mixture are the distinguishing features of the RESS process [25]. The RESS process can 
produce particles with submicroscopic size with narrow size distribution. The greatest advantage of the 
RESS process is the condition is mild and green, and especially it can be well used in the materials 
which are temperature-sensitive and have strong biological activity.  In this study, artemisinin was 
micronized by RESS process with the purpose to improve the water solubility and bioavailability of 
artemisinin. The characterization of the artemisinin particles was carried out using  SEM, LC-MS, 
FTIR, DSC and XRD. 
2. Results and Discussion 
2.1. Optimization of RESS-SC Micronization 
The assignment of the experiment and the collected data for MPS of micronized artemisinin is shown 
in Table 1. The results showed that access to the largest of artemisinin micronization powder size was  
2100 nm, the minimum diameter of 620 nm. According to the R value we can see that the influence to the 
MPS of micronized artemisinin decreases in the order: A > B > C > D, the best operating conditions is 
A4B4C3D4 (62 ° C, 25 MPa, 45 ° C and 1000 μm). Through a confirmatory test, smaller micronized 
artemisinin was obtained, with a minimum diameter of 550 nm. The yield of micronized artemisinin was 
about 86.2%. 
The relationships between the MPS of micronized artemisinin and process parameters are shown in 
Figure  2.  As  seen  in  Figure  2,  the  MPS  of  micronized  artemisinin  decreased  as  the  extraction 
temperature  increased  from  32  to  62  ° C  and  extraction  pressure  increased  from  10  to  25  MPa, 
respectively. However, precipitation temperature and nozzle diameter within their given operational 
range have no significant influences on the MPS. Solution saturation has a significant effect on the 
crystallization  of  the  solute,  the  greater  degree  of supersaturation, the smaller particle size of the 
crystal precipitation. It can be known from the best operating conditions, the smaller powder particle 
size had been obtained in the condition of high temperature and pressure. This is due to the increase of 
temperature and pressure that led to the rapid expansion of supercritical fluid and formed a very high 
saturation, and the solute formed of tiny crystalline nuclei in an instant. 
The data are analyzed using Design Expert 7.0 software for evaluating the effect of each parameter on 
the optimization criteria. Table 2 lists the data of the ANOVA table of this experiment. The ANONA 
analysis revealed that each of the four factors exerted influence on the MPS of micronized artemisinin in 
the  selected  ranges,  among  which  extraction  temperature  and  pressure  were  identified  as  the  most 
important  determinant  based  on  ANOVA  with  95%  confidence.  Moreover,  the  particle  size  of 
micronized artemisinin decreased with increasing extraction temperature and pressure. The increasing Int. J. Mol. Sci. 2012, 13  5063 
 
 
solubility of artemisinin in SC-CO2 was determined as temperature or pressure increase [26]. The smaller 
particle size was obtained due to higher supersaturation caused by the higher solubility of artemisinin. 
Table 1. Experimental conditions and results for the artemisinin RESS processes. 
Trial No. 
Extraction  
Temperature 
Extraction 
Pressure 
Precipitation 
Temperature 
Nozzle 
Diameter 
MPS 
  (° C)  (MPa)  (° C)  (μm)  (nm) 
1  1(32)  1(10)  1(25)  1(150)  2100 
2  2(42)  1(10)  2(35)  2(200)  1930 
3  3(52)  1(10)  3(45)  3(300)  1725 
4  4(62)  1(10)  4(55)  4(1000)  1571 
5  1(32)  2(15)  3(45)  2(200)  1459 
6  2(42)  2(15)  4(55)  1(150)  1411 
7  3(52)  2(15)  1(25)  4(1000)  1358 
8  4(62)  2(15)  2(35)  3(300)  992 
9  1(32)  3(20)  4(55)  3(300)  840 
10  2(42)  3(20)  3(45)  4(1000)  880 
11  3(52)  3(20)  2(35)  1(150)  740 
12  4(62)  3(20)  1(25)  2(200)  680 
13  1(32)  4(25)  2(35)  4(1000)  910 
14  2(42)  4(25)  1(25)  3(300)  730 
15  3(52)  4(25)  4(55)  2(200)  660 
16  4(62)  4(25)  3(45)  1(150)  620 
K1 
a  1831.5  1327.25  1217.75  1217.0   
K2  1305.0  1237.75  1182.25  1143.0   
K3  785.0  1120.75  1071.75  1171.0   
K4  730.0  965.75  1179.75  1120.5   
R 
b  1101.5  361.5  146.0  96.5   
Optimal level  A4  B4  C3  D4   
a Ki
A = ∑(mean particle size at Ai)/4, the mean values of mean particle size for a certain factor at each level 
with standard deviation; 
b Ri
A = max{Ki
A} − min{Ki
A}. 
Table 2. ANONA analysis of four parameters for RESS micronization of artemisinin. 
Source  Sum of Squares (SS)  Degrees of Freedom (df)  F-Ratio  F0.05  Type of Effect 
A  3189716.75  3  334.045  9.280  Significant 
B  293032.75  3  30.688  9.280  Significant 
C  47900.75  3  5.016  9.280   
D  20744.75  3  2.173  9.280   
Error  9548.75  3  22075     Int. J. Mol. Sci. 2012, 13  5064 
 
 
Figure  2.  The  effect  of  each  parameter  on  the  MPS  of  micronized  artemisinin.  
(a)  Extraction  temperature;  (b)  Extraction  pressure;  (c)  Precipitation  temperature  and  
(d) Nozzle diameter. 
 
2.2. Particle Morphology 
Particle  morphology  and  particle  size  were  defined  on  a  visual  basis.  The  photograph  of  the 
conventionally  crystallized  unprocessed  drug  shows  narrow  needle-like  crystals  (Figure  3a).  It  is 
visible  from  Figure  3c  that  unprocessed  artemisinin  particles  are  irregular  needle-shaped  crystals, 
ranging in length from 30 µm to 1200 µm. Processed artemisinin by RESS is a loose white powder 
RESS (Figure 3b). The SEM image shows that processed artemisinin is lamelliform particles, ranging 
in length from 400 nm to 850 nm (Figure 3d). A tendency to form aggregates is noted, this is because 
of smaller particle size and surface activity of the high reunion. It should be mentioned that these 
aggregates are completely separated when the powder is suspended in water. Int. J. Mol. Sci. 2012, 13  5065 
 
 
Figure  3.  The  particle  morphology  of  unprocessed  and  processed  artemisinin.  
(a)  photograph  of  unprocessed  artemisinin;  (b)  photograph  of  processed  artemisinin;  
(c) SEM image of unprocessed artemisinin; (d) SEM image of processed artemisinin. 
 
2.3. FTIR Analysis 
The FTIR spectra of unprocessed and processed artemisinin were taken to obtain information on the 
change of chemical structure after RESS processing presented in Figure 4. It can be seen from Figure 4 
that  FTIR  spectra  between  unprocessed  and  processed  artemisinin  do  not  show  any  significant 
differences.  The  assignment  of  bands  are  as  follows:  995,  928  and  833  cm
−1  (C-C  stretching 
vibrations),  1027  cm
−1  and  1012  cm
−1  (-C-O-stretching  vibrations),  1117  cm
−1  (-O-  stretching 
vibrations), 1384 cm
−1 (-CH3 stretching vibrations), 1456 cm
−1 (-CH2 Bending vibrations), 1738 cm
−1 
(C=O stretching vibrations), 2953 cm
−1 and 2980 cm
−1 (-CH2 stretching vibrations). 
Figure 4. Comparison of artemisinin FTIR spectra before and after RESS processing. 
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2.4. LC-MS Analysis 
The full scan mass spectra of unprocessed and processed artemisinin after direct injection in mobile 
phase are presented in Figure 5. As seen from Figure 5, no modification occurred in molecular weight. 
The protonated molecule was detected at m/z 283.34 for [M + H]
+. This mass agrees with the published 
structure C15H22O5 of artemisinin. The two forms of artemisinin exhibited the same molecular weight 
(282.34). Therefore, the RESS process has not induced degradation of artemisinin. 
Figure 5. LC-MS analysis of artemisinin before and after RESS processing. (a) unprocessed 
artemisinin; (b) processed artemisinin. 
 
2.5. DSC Analysis 
The obtained particles were characterized by DSC (Figure 6). The melting point of unprocessed 
artemisinin is 153.3 ° C whereas RESS-SC processed artemisinin has a melting point of 147.4 ° C. The 
melting point of processed artemisinin was about 5.9 ° C less than that of unprocessed artemisinin. 
Figure 6 shows also the heat flow with temperature plot of unprocessed and processed artemisinin Int. J. Mol. Sci. 2012, 13  5067 
 
 
particles. The decrease of heat flow for processed artemisinin can be attributed to the lowering of the 
crystallinity after RESS-SC processing. 
Figure 6. DSC analysis of before and after RESS processing. (a) Unprocessed artemisinin; 
(b) processed artemisinin. 
 
2.6. X-ray Analysis 
Figure 7 shows the XRD results for processed and unprocessed artemisinin particles. Though the 
peaks are at the same angles (2θ = 11.94° , 18.36° , 20.14° ), the intensity of the peaks are lower for 
RESS processed particles. It can be seen from Figure 7 that the initial state of unprocessed artemisinin 
is crystalline. The crystalline structure is partly retained because the main peaks are still present in the 
processed artemisinin trace. Lower intensity can be attributed to the lowering of crystallinity of the 
particles  after  RESS  processing.  Less  crystalline  and  smaller  drug  particles  are  higher  in  the 
dissolution rate or bioavailability than crystals and, thus, the therapeutic action is obtained in shorter 
times [27]. Moreover, lower crystallinity materials  (with partial  crystalline structure) can be more 
stable  in  time  than  amorphous  ones.  The  effect  of  the  storage  time  on  the  morphology  and  the 
crystalline structure of artemisinin particles will be assessed in a future work. 
Figure 7. Comparison of artemisinin XRD traces before and after RESS processing. 
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2.7. Bulk Density 
The results of bulk density determination obtained are presented in Table 3. The results show that 
bulk density of RESS-SC processed artemisinin is significantly less than unprocessed artemisinin. 
Formation of micronization with smaller particle size could be the reason for the lowering of intensity. 
This can increase the liquidity of drug particles when they are applied for medicinal preparations. 
Table 3. The comparation of bulk density between unprocessed and processed artemisinin. 
Artemisinin  Quality (g)  Volume (mL)  Density (g/mL) 
unprocessed  2.77   5  0.554  
processed  0.64   5  0.128 
3. Experimental Section 
3.1. Materials 
Artemisinin was obtained from Xian Sino-herb Biotechnology Co., Ltd. (Shanxi, China). It was 
extracted from Artemisia annua L., and then purified. It is a colorless needle crystal and the purity of 
mass fraction was above 98.5%. Further purification was not performed. High purity CO2 (99.99% pure) 
was purchased from Liming gas company of Harbin (Heilongjiang, China). 
3.2. RESS Apparatus 
The schematic of RESS-SC process is shown in Figure 8. The apparatus consists of extraction 
chamber and precipitation chamber. In each experiment, 1000 mL stainless steel extraction column 
was used and 0.2 μm spare frits filters were placed at both ends for distribution of supercritical CO2. 
The purified gaseous CO2 is liquefied and subcooled in a liquid CO2 tank, and then compressed to the 
desired pressure with a high-pressure syringe pump. The preheated CO2 entered the extraction unit 
using a heat exchanger and formed a supercritical solution. The extraction column with material was 
placed  in  the  temperature-controlled  extraction  chamber  and  equilibrated  to  the  pre-set  extraction 
temperature. The solvent (CO2) was delivered to the system at the extraction pressure by high-pressure 
syringe pumps and entered the extraction column. Subsequently, the supercritical solution with a mass 
flow of 6.0 kg/h was expanded rapidly through a nozzle into the precipitation chamber at atmospheric 
pressure. The CO2 mass flow through the nozzle is measured with a mass flow meter. The crystals 
produced were  collected by a  cyclone  collector that was  connected to  precipitation  chamber.  The 
experiments were carried out in batch mode. In each experiment the system was given 30 min to reach 
steady state condition and then the supercritical fluid was expanded for 10 min in the precipitation vessel. Int. J. Mol. Sci. 2012, 13  5069 
 
 
Figure 8. Schematic diagram of the rapid expansion of supercritical solutions (RESS) apparatus. 
 
3.3. Optimization of RESS-SC Micronization 
Artemisinin was put in the form of powder in the extraction chamber. Then artemisinin was dissolved 
in  supercritical  CO2  fluid.  The  artemisinin/CO2  solution  was  sprayed  rapidly  through  a  nozzle  into 
precipitation chamber from a desired pressure to atmospheric pressure. The parameters affecting particle 
size include extraction pressure, extraction temperature, nozzle diameter and precipitation temperature. 
According to solubility of artemisinin in supercritical carbon dioxide [26], an orthogonal design OA16 (4)
5 
was selected for optimization of operating condition of artemisinin micronization by the RESS process. 
As  indicated  in  Table  4,  the  RESS  experiment  is  carried  out  with  4  factors  and  4  levels,  namely 
extraction  temperature  (32,  42,  52,  62  ° C),  extraction  pressure  (10,  15,  20,  25  MPa),  precipitation 
temperature (25, 35, 45, 55 ° C), and nozzle diameter (150, 200, 300, 1000 μm). The range of each factor 
level is based on the results of preliminary experiments. The MPS (nm) of micronized artemisinin is the 
dependent  variable.  The  data  are  analyzed  using  the  Design  Expert  7.0  software  (Stat-Ease,  Inc.: 
Minneapolis, MN, USA). 
Table 4. The factors and levels of the orthogonal array design. 
Factors 
(A) Extraction 
Temperature 
(B) Extraction 
Pressure 
(C) Precipitation 
Temperature 
(D) Nozzle 
Diameter 
Levels  (° C)  (MPa)  (° C)  (μm) 
1  32  10  25  150 
2  42  15  35  200 
3  52  20  45  300 
4  62  25  55  1000 Int. J. Mol. Sci. 2012, 13  5070 
 
 
3.4. Analytical Methods 
3.4.1. Observation of Particle Morphology 
A SEM (Quanta 200, FEI Company, Eindhoven, The Netherlands) was used to observe the shape 
and measure the mean particle diameter of the unprocessed and processed artemisinin. 
3.4.2. FTIR Analysis 
The unprocessed and processed artemisinin were diluted with KBr mixing powder at 1% and pressed 
to obtain self-supporting disks, separately. The FTIR spectrum was obtained by MAGNA-IR560 E.S.P 
(Nicolet, Madison, WI, USA) and recorded in the wave number range of 4000–500 cm
−1 at a resolution  
of 4 cm
−1. 
3.4.3. LC-MS Analysis 
The unprocessed and processed artemisinin were dissolved separately in methanol. High performance 
liquid chromatography-mass spectrometry (LC-MS) was obtained by analyst 1.4 of AB API 3000 
(Foster City, CA, USA). The mass spectrometer was operated in positive ion mode. 
3.4.4. DSC Analysis 
Thermal analysis was carried out using DSC (TA instruments, model DSC 204) for processed and 
unprocessed artemisinin particles. Analysis was performed for 5.0 mg samples at a temperature heating 
rate of 5 ° C/min and a temperature range of 20–200 ° C. 
3.4.5. X-ray Diffraction 
X-ray  diffraction  patterns  were  collected  in  transmission  using  an  X-ray  diffractometer  with  a 
rotating  anode  (Xpert-Pro,  Philips,  Almelo,  The  Netherlands)  with  Cu  Kα1  radiation  generated  at  
30 mA and 50 kV. The powders of unprocessed and processed artemisinin were filled to same depth 
inside the sample holder by leveling with spatula and scanning rate (4° /min) was same for all XRD 
analysis.  
3.4.6. Bulk Density 
Bulk  density  of  the  powders  was  determined  using  the  method  described  in  the  United  States 
Pharmacopoeia XXVII [28]. Pass a quantity of powder sufficient to complete the test through a 1.0 mm 
sieve. Carefully scrape the excess powder from the top of the vessel (volume = v0). The mass (m0) of 
the powder was determined to the nearest 0.1 percent by subtraction of the previously determined mass 
of the empty measuring vessel. The bulk density (g/mL) was calculated by the formula m0/v0 and 
recorded the average of three determinations using three different powder samples. Int. J. Mol. Sci. 2012, 13  5071 
 
 
4. Conclusions  
In this study, artemisinin was micronized by the rapid expansion of supercritical fluids (RESS). 
Micronization particles of artemisinin with a MPS of 550 nm are obtained (at extraction temperature  
of 62 °C , extraction pressure of 25 MPa, precipitation temperature of 45 °C  and nozzle diameter of  
1000 μm). The particle size of micronized artemisinin decreased with increasing extraction temperature 
and pressure.  The  RESS process  did not  induce the degradation of artemisinin and the processed 
artemisinin particles have lower crystallinity and melting point. The bulk density of artemisinin was 
determined before and after RESS process, and the obtained results showed that it passes from an 
initial density of 0.554 to 0.128 g cm
−3 after the processing. The decrease in bulk density of the 
micronized powder can increase the liquidity of drug particles when they are applied for medicinal 
preparations.  This  is  due to  the  uniform  size and good surface  flatness of micronized  artemisinin 
powder. These results suggest that micronized powder of artemisinin can be great potential in drug 
delivery systems. 
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